Anemia is a new complication in Fabry disease: data from the Fabry Outcome Survey.
Standard
Anemia is a new complication in Fabry disease: data from the Fabry Outcome Survey. / Kleinert, Julia; Dehout, François; Schwarting, Andreas; Lorenzo, de; García, Abelardo; Ricci, Roberta; Kampmann, Christoph; Beck, Michael; Ramaswami, Uma; Gal, Andreas; Gal, Andreas; Houge, Gunnar; Widmer, Urs; Mehta, Atul; Sunder-Plassmann, Gere.
in: KIDNEY INT, Jahrgang 67, Nr. 5, 5, 2005, S. 1955-1960.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Anemia is a new complication in Fabry disease: data from the Fabry Outcome Survey.
AU - Kleinert, Julia
AU - Dehout, François
AU - Schwarting, Andreas
AU - Lorenzo, de
AU - García, Abelardo
AU - Ricci, Roberta
AU - Kampmann, Christoph
AU - Beck, Michael
AU - Ramaswami, Uma
AU - Gal, Andreas
AU - Gal, Andreas
AU - Houge, Gunnar
AU - Widmer, Urs
AU - Mehta, Atul
AU - Sunder-Plassmann, Gere
PY - 2005
Y1 - 2005
N2 - BACKGROUND: The prevalence and causes of anemia among patients with Fabry disease are unknown. METHODS: In a cross-sectional study we examined hemoglobin concentrations of patients with Fabry disease using a large international database, the Fabry Outcome Survey (FOS), and analyzed the association of renal function, heart failure, gastrointestinal symptoms, and inflammation, with anemia (hemoglobin 90 mL/min/1.73 m(2)] and anemia, heart failure [New York Heart Association (NYHA) class II to IV] and/or elevated C-reactive protein (CRP) levels were documented in 82% of patients. Up to 67% of patients with decreased estimated GFR presented with anemia. There was also a trend for lower hemoglobin levels among patients with signs of inflammation (defined by an elevated CRP level). We observed no association of the presence of gastrointestinal symptoms with anemia. Analyses in 53 patients receiving enzyme replacement therapy for up to 2 years, suggest no effect on anemia. CONCLUSION: The results of this study point to a high prevalence of anemia among patients with Fabry disease that is in most instances related to impaired renal function, heart failure, and inflammation. This finding may be of clinical relevance, because anemia is a major risk factor for patients with kidney disease, heart failure, or stroke, which are important manifestations of Fabry disease.
AB - BACKGROUND: The prevalence and causes of anemia among patients with Fabry disease are unknown. METHODS: In a cross-sectional study we examined hemoglobin concentrations of patients with Fabry disease using a large international database, the Fabry Outcome Survey (FOS), and analyzed the association of renal function, heart failure, gastrointestinal symptoms, and inflammation, with anemia (hemoglobin 90 mL/min/1.73 m(2)] and anemia, heart failure [New York Heart Association (NYHA) class II to IV] and/or elevated C-reactive protein (CRP) levels were documented in 82% of patients. Up to 67% of patients with decreased estimated GFR presented with anemia. There was also a trend for lower hemoglobin levels among patients with signs of inflammation (defined by an elevated CRP level). We observed no association of the presence of gastrointestinal symptoms with anemia. Analyses in 53 patients receiving enzyme replacement therapy for up to 2 years, suggest no effect on anemia. CONCLUSION: The results of this study point to a high prevalence of anemia among patients with Fabry disease that is in most instances related to impaired renal function, heart failure, and inflammation. This finding may be of clinical relevance, because anemia is a major risk factor for patients with kidney disease, heart failure, or stroke, which are important manifestations of Fabry disease.
M3 - SCORING: Zeitschriftenaufsatz
VL - 67
SP - 1955
EP - 1960
JO - KIDNEY INT
JF - KIDNEY INT
SN - 0085-2538
IS - 5
M1 - 5
ER -
